This position statement explores the intricate relationship between alcohol intake and metabolic dysfunction in the context of the 2023 nomenclature for steatotic liver disease (SLD). Recent and lifetime alcohol use should be accurately assessed in all patients with SLD to facilitate classification of alcohol use in grams of alcohol per week. Alcohol biomarkers (phosphatidylethanol), use of validated questionnaires, and collateral information from friends and relatives could help facilitate differentiation between alcohol-related liver disease per se and liver disease with both metabolic and alcohol-related liver disease. Heavy alcohol use can contribute to cardiometabolic risk factors such as high blood pressure, hypertriglyceridemia, and hyperglycemia. As a result, caution should be exercised in the application of only one metabolic dysfunction criterion to diagnose metabolic dysfunction-associated steatotic liver disease, as suggested in the 2023 nomenclature document, particularly in individuals exceeding weekly alcohol use thresholds of 140 g for women and 210 g for men. Additionally, metabolic dysfunction and alcohol use should be reassessed over time. This approach could ensure a more accurate prognosis and effective management of SLD addressing both metabolic and alcohol-related factors.

Objective To investigate the status of quality control of medical electron linear accelerators and radiation protection of machine rooms housing these accelerators in Shandong Province. Methods A total of 52 medical electron linear accelerators in 40 hospitals across Shandong Province were selected as the study subjects. A series of indicators were tested according to relevant quality control testing specifications and radiation protection testing standards. Statistical analysis was performed using SPSS 25.0. Results The five performance indicators of the 52 medical electron linear accelerators, including offset of the radiation beam axis relative to the equal center point (hereinafter referred to as the equal center point offset), dose deviation, output dose repeatability, output dose linearity, and uniformity of the square X-ray radiation field (10 cm × 10 cm), all had a qualified rate of 100%. The dose deviation of accelerators in secondary hospitals was superior to that in tertiary hospitals. The output dose linearity and uniformity of the square X-ray radiation field of accelerators in tertiary hospitals were superior to those in secondary hospitals. All machine rooms housing the investigated medical electron linear accelerators were qualified in radiation protection testing. Conclusion The performance indicators of the medical electron linear accelerators investigated in this study and the radiation protection of machine rooms all complied with national standards. Relevant hospitals should continue to strictly implement radiation protection standards and strengthen the supervision of the equipment sites.

This position statement explores the intricate relationship between alcohol intake and metabolic dysfunction in the context of the 2023 nomenclature for steatotic liver disease (SLD). Recent and lifetime alcohol use should be accurately assessed in all patients with SLD to facilitate classification of alcohol use in grams of alcohol per week. Alcohol biomarkers (phosphatidylethanol), use of validated questionnaires, and collateral information from friends and relatives could help facilitate differentiation between alcohol-related liver disease per se and liver disease with both metabolic and alcohol-related liver disease. Heavy alcohol use can contribute to cardiometabolic risk factors such as high blood pressure, hypertriglyceridemia, and hyperglycemia. As a result, caution should be exercised in the application of only one metabolic dysfunction criterion to diagnose metabolic dysfunction-associated steatotic liver disease, as suggested in the 2023 nomenclature document, particularly in individuals exceeding weekly alcohol use thresholds of 140 g for women and 210 g for men. Additionally, metabolic dysfunction and alcohol use should be reassessed over time. This approach could ensure a more accurate prognosis and effective management of SLD addressing both metabolic and alcohol-related factors.

Resistant ovary syndrome(ROS)and premature ovarian insufficiency(POI)fall under the cat-egory of hypogonadotropic amenorrhea,sharing similar clinical features that often pose challenges in differentiation.ROS can be easily misdiagnosed as POI,which presents a significant obstacle to subsequent treatment.Therefore,it is crucial for patients with fertility requirements to have a clear understanding of the etiology,clinical features,and diagnostic criteria of ROS and POI in order to establish an early diagnosis and develop an appropriate treatment plan.This article provides a systematic and comprehensive discussion on the research progress regarding the eti-ology and pathogenesis,clinical features and diagnosis,as well as individualized management of ROS and POI.The aim is to offer reference for clinicians in achieving early clarification of diagnoses,avoiding misdiagnosis or mistreatment,while assisting patients in improving symptoms and realizing their fertility aspirations through person-alized management.

Resistant ovary syndrome(ROS)and premature ovarian insufficiency(POI)fall under the cat-egory of hypogonadotropic amenorrhea,sharing similar clinical features that often pose challenges in differentiation.ROS can be easily misdiagnosed as POI,which presents a significant obstacle to subsequent treatment.Therefore,it is crucial for patients with fertility requirements to have a clear understanding of the etiology,clinical features,and diagnostic criteria of ROS and POI in order to establish an early diagnosis and develop an appropriate treatment plan.This article provides a systematic and comprehensive discussion on the research progress regarding the eti-ology and pathogenesis,clinical features and diagnosis,as well as individualized management of ROS and POI.The aim is to offer reference for clinicians in achieving early clarification of diagnoses,avoiding misdiagnosis or mistreatment,while assisting patients in improving symptoms and realizing their fertility aspirations through person-alized management.

Intrahepatic cholangiocarcinoma (iCCA) occurs within the liver, between the bile duct and the secondary bile duct. It is the second most common primary liver cancer after hepatocellular carcinoma, and its incidence rate is increasing worldwide. The mortality rate is alarming because of its clinical asymptomatic features (often leading to delayed diagnosis), high invasiveness, and treatment resistance. Early diagnosis, molecular pathological biology, accurate staging, and personalized multidisciplinary treatment are current challenges for researchers and physicians. Furthermore, iCCA is difficult to treat due to its high heterogeneity at the clinical, genomic, epigenetic, and molecular levels. However, recent advances in molecular, surgical, and targeted therapies, along with the recognition that the etiology, risk factors, pathophysiology, molecular biology, and clinical management of iCCA differ completely from those of hilar cholangiocarcinoma (pCCA) and distal cholangiocarcinoma (dCCA), have prompted the International Liver Cancer Association and the European Association for the Study of the Liver to commission international specialized experts to draft evidence-based guidelines for physicians involved in the diagnosis, treatment, and prognosis. Herein, the key points of the guidelines are excerpted.

Intrahepatic cholangiocarcinoma (iCCA) occurs within the liver, between the bile duct and the secondary bile duct. It is the second most common primary liver cancer after hepatocellular carcinoma, and its incidence rate is increasing worldwide. The mortality rate is alarming because of its clinical asymptomatic features (often leading to delayed diagnosis), high invasiveness, and treatment resistance. Early diagnosis, molecular pathological biology, accurate staging, and personalized multidisciplinary treatment are current challenges for researchers and physicians. Furthermore, iCCA is difficult to treat due to its high heterogeneity at the clinical, genomic, epigenetic, and molecular levels. However, recent advances in molecular, surgical, and targeted therapies, along with the recognition that the etiology, risk factors, pathophysiology, molecular biology, and clinical management of iCCA differ completely from those of hilar cholangiocarcinoma (pCCA) and distal cholangiocarcinoma (dCCA), have prompted the International Liver Cancer Association and the European Association for the Study of the Liver to commission international specialized experts to draft evidence-based guidelines for physicians involved in the diagnosis, treatment, and prognosis. Herein, the key points of the guidelines are excerpted.

Objective:To explore the effects of different approaches for second-trimester multifetal pregnancy reduction on pregnancy outcome in women with dichorionic triamniotic (DCTA) triplet.Methods:A retrospective study was performed on 51 women with DCTA triplet pregnancies who were referred to Guangdong Women and Children Hospital for second-trimester multifetal pregnancy reduction from January 2014 to January 2020. All participants were divided into either preventive group ( n=39) or treatment group ( n=12) according to the indication for multifetal pregnancy reduction, and they were further allocated to three subgroups based on different reduction methods, which were reduction to dichorionic twin by radiofrequency ablation (RFA) (RFA subgroup), reduction to monochorionic singleton (KCl-singleton subgroup) or monochorionic twin (KCl-twin subgroup) by cardiac injection of potassium chloride. Pregnancy loss rate, neonatal birth weight, gestational age at delivery, incidence of intrauterine death, and neonatal death were compared and analyzed between different groups using t-test, analysis of variance, Chi-square test, Fisher's exact test and Bonferroni correction. Results:(1) The mean gestational week at operation in the treatment group was significantly later than that in the preventive group [(18.5±3.1) vs (15.0±2.3) weeks, t=-4.209, P<0.001]. In the preventive group, the mean gestational week at operation in the RFA subgroup was later than the KCl-singleton and KCl-twin subgroup[(17.2±1.6) vs (13.8±1.5) and (12.7±1.0) weeks, t=6.630 and 3.875, respectively, both P<0.05]. (2) The postoperative pregnancy loss rate in the preventive group was decreased compared with the treatment group [10.3%(4/39) vs 5/12, Fisher's exact test, P<0.05], and the live birth ratio was increased [ 85.7%(48/56) vs 10/18, χ2=5.640, P=0.018]. No live birth infants with birth weight <1 500 g was reported in the KCl-singleton subgroup in preventive group, and the statistical significance was observed in the intra-group differences ( P<0.05) rather than the pairwise comparison differences in the preventive group. For the proportion of live births, there was a statistically significant difference in the intra-group comparison in the treatment group, which was higher in the RFA subgroup than that in the KCl-twin subgroup (6/6 vs 1/6, P=0.045). No significant difference was revealed among pregnancy loss rate, gestational weeks at delivery, the mean birth weight, premature delivery <32 gestational weeks, and full-term birth rate among three different approaches within the two groups. (3) No monochorionic twin complications or perinatal death occurred in any RFA or KCl-singleton subgroups in the two groups. In the KCl-twin subgroups including five cases with ten fetuses, including three live birth, four miscarriage, three intrauterine death occured, while no neonatal death was reported. One case with selective fetal uterine growth restriction in the preventive group delivered two live births, and one case with twin-to-twin transfusion syndrome in the treatment group had intrauterine death in one fetus and one survival neonate. Conclusions:The pregnancy outcome of multifetal pregnancy reduction to dichorionic diamniotic twins by RFA or reduction to singleton by cardiac injection of potassium chloride are comparative in women with DCTA triplet, regardless of whether it is a preventive or therapeutic reduction.

Objective To investigate the value of prenatal ultrasound in prognosis assessment of congenital diaphragmatic hernia.Methods The ultrasonographic features of 65 fetuses with congenital diaphragmatic hernia were analyzed,which were confirmed by after birth surgery or examination.The lung-to-head ratio (LHR) of unaffected side and O/E LHR (LHR compared to normal fetuses on same gestational weeks) were obtained,and then the relationship with the prognosis of neonates were analyzed.Results In 65 cases,45 fetuses survived and 8 fetuses died after surgery,while 12 cases did not undergo surgery and death promptly.Overall mortality was 30.77％ (20/65).In 12 hepatic intrathoracic type of diaphragmatic hernia cases,the mortality rate was 66.67 ％ (8/12).In 53 hepatic intra-abdominal type of diaphragmatic hernia cases,the mortality rate was 22.64 ％ (12/53).In 9 cases combined with other structural abnormalities,there were 8 cases were dead and 6 cases (6/8) with abnormal chest structure.LHR values were from 0.40 to 2.72,the average value was 1.59±0.69.It showed statistical difference on the mortality rate in fetus of congenital diaphragmatic hernia with different LHR (x2 =19.360,P＜0.001),The mortality rate in fetal of congenital diaphragmatic hernia with LHR 1.0 or less was higher than that with LHR ＞1.0.O/E LHR measurement values were from 23％ to 90％ and the average value was (58.25±17.61) ％.It showed statistical difference on the mortality rate in fetus of congenital diaphragmatic hernia with different O/E LHR (x2 15.261,P=0.002).The mortality rate in fetal of congenital diaphragmatic hernia with O/E LHR ≤45 ％ was higher than that with O/E LHR＞45 ％.Conclusion The prenatal ultrasound can be used to diagnose congenital diaphragmatic hernia,and to assess the development of unaffected lung and prognosis.